Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBI’s outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries.
Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBIs outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries. In an Aug. 12 statement, San Diego-based MBI emphasized that it did not endorse the $2.00 per share offer, as stockholders could get a higher price for their shares on the New York Stock Exchange, which on Aug. 11 posted a closing price per share of $2.25. Towanda Partners did not contact MBI before making its offer, which expired on Aug. 16.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
2 Commerce Drive
Cranbury, NJ 08512